Primary Biliary Cholangitis (PBC) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic condition in which the liver’s tiny bile ducts become damaged, inflamed, and eventually destroyed. Bile is a fluid made in the liver. It aids digestion and helps the body eliminate toxins, cholesterol and worn-out red blood cells. When the bile ducts are harmed, bile can back up in the liver, causing irreversible scarring of the liver tissue (cirrhosis). The continuous destruction of small and medium bile ducts is mediated by activated CD4 and CD8 lymphocytes.
- The prevalence of PBC has been estimated to be approximately 51 to 65 cases per 100,000 population in the United States.
Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Primary Biliary Cholangitis (PBC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Primary Biliary Cholangitis (PBC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.